Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 12/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 9/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 7/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.47 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.47 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | CYP51A1 | Q16850 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.42 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.42 |
| ▸ | CYP8B1 | Q9UNU6 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8718853 | 1.00 | CYP3A4 (0.48) | CYP3A4CYP2C9CYP2C19CYP19A1CYP11B1 | |
| SCHEMBL30121613 | 1.00 | CYP3A4 (0.48) | CYP3A4CYP2C9CYP2C19CYP19A1CYP11B1 | |
| SCHEMBL8718832 | 1.00 | CYP3A4 (0.48) | CYP3A4CYP2C9CYP2C19CYP19A1CYP11B1 | |
| Methane SCHEMBL7967605 | 0.99 | CYP3A4 (0.47) | CYP3A4CYP2C9CYP2C19CYP19A1CYP11B1 | |
| SCHEMBL13916324 | 0.91 | CYP3A4 (0.44) | CYP3A4CYP2C9CYP2C19CYP19A1CYP11B1 | |
| SCHEMBL9198691 | 0.91 | CYP3A4 (0.44) | CYP3A4CYP2C9CYP2C19CYP19A1CYP11B1 | |
| SCHEMBL7639548 | 0.91 | CYP3A4 (0.43) | CYP3A4CYP2C9CYP2C19CYP19A1CYP11B1 | |
| SCHEMBL28002097 | 0.91 | CYP3A4 (0.43) | CYP3A4CYP2C9CYP2C19CYP19A1CYP11B1 | |
| SCHEMBL12186485 | 0.88 | CYP3A4 (0.42) | CYP3A4CYP2C9CYP2C19CYP19A1CYP11B1 | |
| SCHEMBL12186494 | 0.88 | CYP3A4 (0.42) | CYP3A4CYP2C9CYP2C19CYP19A1CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 121 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060252940-A1 | CRYSTALLINE 1-[2-(2,4-DIFLUOROPHENYL)-OXIRANYL METHYL]-1H-1,2,4-TRIAZOLE | DR. REDDY'S LABORATORIES, INC. | 2006-11-09 | — | — | US | claimed |
| EP-1278755-A2 | AZOLE COMPOUNDS AS THERAPEUTIC AGENTS FOR FUNGAL INFECTIONS | Ranbaxy Laboratories, Limited (IN) | 2003-01-29 | — | — | EP | claimed |
| WO-2001066551-A2 | AZOLE COMPOUNDS AS THERAPEUTIC AGENTS FOR FUNGAL INFECTIONS | RANBAXY LABORATORIES LIMITED (IN) | 2001-09-13 | — | — | WO | claimed |
| EP-0967210-A1 | PROCESS FOR PREPARING BIOLOGICALLY ACTIVE DERIVATIVES OF 1,2,4-TRIAZOL AND INTERMEDIARIES USEFUL IN THIS PROCESS | CENTRO GENESIS PARA LA INVESTIGACION, S.L. (ES) | 1999-12-29 | — | — | EP | claimed |
| US-5861516-A | Process for preparing an antifungal azole with hydrazino and amidrazone intermediates | ZENECA LIMITED (GB) | 1999-01-19 | — | — | US | claimed |
| EP-0775121-A1 | PROCESS FOR PREPARING AN ANTIFUNGAL AZOLE WITH HYDRAZINO AND AMIDRAZONE INTERMEDIATES | ZENECA LIMITED (GB) | 1997-05-28 | — | — | EP | claimed |
| WO-1996004256-A1 | PROCESS FOR PREPARING AN ANTIFUNGAL AZOLE WITH HYDRAZINO AND AMIDRAZONE INTERMEDIATES | ZENECA LIMITED (GB) | 1996-02-15 | — | — | WO | claimed |
| EP-4638448-A1 | CONJUGATES COMPRISING ANTIFUNGALS AND CASEIN KINASE (CK1) INHIBITORS AND METHODS OF USE THEREOF | Bright Angel Therapeutics Inc. (CA) | 2025-10-29 | — | — | EP | disclosed |
| US-20240424113-A1 | CONJUGATES COMPRISING ANTIFUNGALS AND HEAT SHOCK PROTEIN 90 (HSP90) INHIBITORS AND METHODS OF USE THEREOF | BRIGHT ANGEL THERAPEUTICS INC. (CA) | 2024-12-26 | — | — | US | disclosed |
| EP-4419531-A1 | CONJUGATES COMPRISING ANTIFUNGALS AND HEAT SHOCK PROTEIN 90 (HSP90) INHIBITORS AND METHODS OF USE THEREOF | Bright Angel Therapeutics Inc. (CA) | 2024-08-28 | — | — | EP | disclosed |
| US-20240246920-A1 | TRIAZOLE DERIVATIVES WITH ANTIFUNGAL ACTIVITY | KING'S COLLEGE LONDON (GB) | 2024-07-25 | — | — | US | disclosed |
| WO-2024130408-A1 | CONJUGATES COMPRISING ANTIFUNGALS AND CASEIN KINASE (CK1) INHIBITORS AND METHODS OF USE THEREOF | BRIGHT ANGEL THERAPEUTICS INC. (CA) | 2024-06-27 | — | — | WO | disclosed |
| CN-117658933-A | 1,2, 4-triazolol substituted benzenesulfonamide derivatives | 贵阳学院 | 2024-03-08 | — | — | CN | disclosed |
| US-4885294-A | AGRICULTURE, HUMANS | PFIZER INC. (US) | 1989-12-05 | — | — | US | disclosed |
| EP-0329711-A1 | 2,4,4-TRI- AND 2,2,4,4-TETRA SUBSTITUTED-1,3-DIOXOLANE COMPOUNDS | SCHERING CORPORATION (US) | 1989-08-30 | — | — | EP | disclosed |
| EP-0321131-A2 | Triazole antifungal agents | Pfizer Limited (GB) | 1989-06-21 | — | — | EP | disclosed |
| US-4788190-A | 2,4,4-tri- and 2,2,4,4-tetra substituted-1,3-dioxolane antifungal, antiallergy compounds | SCHERING CORPORATION (US) | 1988-11-29 | — | — | US | disclosed |
| EP-0278105-A1 | 2,4,4-Tri- and 2,2,4,4-tetra-substituted-1,3-dioxolane | SCHERING CORPORATION (US) | 1988-08-17 | — | — | EP | disclosed |
| WO-1988005048-A1 | 2,4,4-TRI- AND 2,2,4,4-TETRA SUBSTITUTED-1,3-DIOXOLANE COMPOUNDS | SCHERING CORPORATION (US) | 1988-07-14 | — | — | WO | disclosed |
| EP-0174769-A1 | Antifungal azole compounds | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1986-03-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252940-A1 | CRYSTALLINE 1-[2-(2,4-DIFLUOROPHENYL)-OXIRANYL METHYL]-1H-1,2,4-TRIAZOLE | CYP2F1, CYP4B1, CYP3A4 | CYP3A4 3/4885CYP2C9 28/4885CYP2C19 21/4885 |
| US-20240246920-A1 | TRIAZOLE DERIVATIVES WITH ANTIFUNGAL ACTIVITY | RIF1, NAT1, POLR1C | CYP3A4 19/4885CYP2C9 50/4885CYP2C19 25/4885 |
| US-20240424113-A1 | CONJUGATES COMPRISING ANTIFUNGALS AND HEAT SHOCK PROTEIN 90 (HSP90) INHIBITORS AND METHODS OF USE THEREOF | HSP90AB1, HSP90B1, HSP90AA1 | CYP3A4 1741/4885CYP2C9 1333/4885CYP2C19 1151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.